Monitor upcoming clinical data readouts for IPH4502 and monalizumab, and the initiation of the TELLOMAK-3 Phase 3 study for lacutamab, as these are key catalysts for 2026. The CMO transition is a routine leadership change and unlikely to materially impact near-term stock price.
Price Chart
Executive Summary
Innate Pharma announced the appointment of Markus Jensen as Chief Medical Officer, effective June 1, 2026, succeeding Sonia Quaratino. The company also reiterated plans to advance lacutamab into the TELLOMAK-3 Phase 3 study, targeting an accelerated approval filing based on existing Phase 2 data, with three key developments expected in 2026 including clinical results for IPH4502 and monalizumab.
Key Facts
- Markus Jensen appointed Chief Medical Officer effective June 1, 2026, succeeding Sonia Quaratino.
- Innate plans to advance lacutamab into the TELLOMAK-3 Phase 3 study for T-cell lymphomas.
- Lacutamab has received Fast Track, PRIME, Orphan Drug, and Breakthrough Therapy designations.
- Three important developments expected in 2026: lacutamab Phase 3 start, IPH4502 clinical results, and monalizumab clinical results.
- Sobi partnership supports lacutamab development; Sobi had SEK 28 billion revenue in 2025.
Financial Impact
No financial figures disclosed in the filing.
Risk Factors
- Clinical trial risks for lacutamab, IPH4502, and monalizumab, including potential failure to meet endpoints.
- Regulatory risks associated with accelerated approval filing for lacutamab.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001628280-26-054966 |
| Exhibit: exhibit991.htm | 0001628280-26-054966 |
| Document: a6kincorporatediph-praug10.htm | 0001628280-26-054966 |
| Document: 0001628280-26-054966-index-headers.html | 0001628280-26-054966 |
| Document: 0001628280-26-054966-index.html | 0001628280-26-054966 |
| Document: 0001628280-26-054966.txt | 0001628280-26-054966 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $1.57 | awaiting T+20 | — | $1.46 (−7.01%) |
Oct 20, 2026 6d ago | 6-K | $1.58 | awaiting T+20 | — | $1.46 (−7.48%) |
Sep 17, 2026 5w ago | 6-K | $1.91 $1.48 | ▼ −22.51% | ▼ −23.97% | $1.46 (−23.56%) |
Sep 17, 2026 5w ago | 6-K | $1.91 $1.48 | ▼ −22.51% | ▼ −23.97% | $1.46 (−23.56%) |
Sep 17, 2026 5w ago | 6-K | $1.91 $1.48 | ▼ −22.51% | ▼ −23.97% | $1.46 (−23.56%) |
Sep 16, 2026 5w ago | Press Release | $1.91 $1.48 | ▼ −22.51% | ▼ −23.97% | $1.46 (−23.56%) |
Sep 10, 2026 6w ago | 6-K | $1.88 $1.48 | ▼ −21.28% | ▼ −23.40% | $1.46 (−22.34%) |
Sep 2, 2026 7w ago | 6-K | $2.17 $1.63 | ▼ −24.88% | ▼ −24.80% | $1.46 (−32.72%) |
Aug 14, 2026 10w ago | 6-K | $2.18 $1.85 | ▼ −15.14% | ▼ −13.15% | $1.46 (−33.03%) |
Aug 10, 2026 11w ago | 6-K | $2.22 $2.05 | ▼ −7.66% | ▼ −6.74% | $1.46 (−34.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers